Skip to main content

Tokyo, Published date 8 February, 2019

Technology to support early diagnosis of neurodevelopmental disorders from brain response

Select category Healthcare

Fundamental technology to support the early diagnosis of neurodevelopmental disorders from brain response at the time of medication

Tokyo, February 8, 2019 --- Hitachi, Ltd. (TSE: 6501, Hitachi), Jichi Medical University (JMU), International University of Health and Welfare (IUHW) and Chuo University (Chuo-U) have developed fundamental technology to support the early differential diagnosis of concurrent autism spectrum disorder(1) (ASD) in patients with attention-deficit hyperactivity disorder(2) (ADHD).

The technology automatically analyzes the presence or absence of concurrent ASD when an ADHD patient takes their medication for the first time, by using optical topography(3) to measure brain response. The condition can be predicted with a confirmed accuracy of about 82%. Conventionally, differential diagnosis requires follow-up observations spanning several months. This technique demonstrates the possibility of achieving a diagnosis in about 2 hours. Hitachi, JMU, IUHW and Chuo-U will continue to develop this technology through clinical research, with the aim of realizing a society that supports the healthy development of patients with neurodevelopmental disorders.

MADISON, Wis. U.S., 27 July 2022
Hitachi Chosen as Proton Therapy Provider for UW Health Eastpark Medical Center
Read more Select category Healthcare Manufacturing
Tokyo, Japan, 6 January 2021
Olympus and Hitachi Announce Long-Term Business Alliance
Read more Select category Corporate News Healthcare Research & Development